Tags

Type your tag names separated by a space and hit enter

Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease.

Abstract

The present study investigated the antibody response against influenza vaccine and also the efficacy of vaccination on clinical findings in patients with Chronic Obstructive Pulmonary Disease (COPD) following influenza vaccination. A total of 82 cases with COPD (44 cases as vaccinated and 38 cases as unvaccinated) were evaluated clinically and 21 healthy volunteers were also included in the study as a control group. Influenza (A and B) Ig M and Ig G parameters were analyzed quantitatively in blood samples of the vaccinated group and healthy volunteers by ELISA method once before vaccination and one month and one year after vaccination. The presence of dyspnoea, increased sputum production and/or purulence were accepted as criteria of acute exacerbation. The number of hospital presentations was significantly lower in the vaccinated group and higher in severe cases with COPD in unvaccinated group. Vaccinated cases in the study group experienced significantly fewer episodes of pneumonia, hospitalization and intensive care. Quantitative influenza (A and B) antibody IgG levels significantly increased in these patients as well. In conclusion, seasonal influenza vaccination with the trivalent influenza split virion vaccine especially in severe or very severe COPD patients who need hospitalization was evaluated as beneficial in clinical use.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Dr. Suat Seren Training and Research, Hospital for Chest Diseases and Surgery, Department of Chest Diseases, Izmir Turkey. drceydaanar@hotmail.com

    , , , ,

    Source

    The new microbiologica 33:2 2010 Apr pg 117-27

    MeSH

    Adult
    Aged
    Antibodies, Viral
    Female
    Hospitalization
    Humans
    Immunoglobulin G
    Immunoglobulin M
    Influenza A Virus, H1N1 Subtype
    Influenza A Virus, H3N2 Subtype
    Influenza B virus
    Influenza Vaccines
    Influenza, Human
    Male
    Middle Aged
    Pulmonary Disease, Chronic Obstructive
    Treatment Outcome
    Vaccination

    Pub Type(s)

    Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    20518273

    Citation

    Anar, Ceyda, et al. "Evaluation of Clinical Data and Antibody Response Following Influenza Vaccination in Patients With Chronic Obstructive Pulmonary Disease." The New Microbiologica, vol. 33, no. 2, 2010, pp. 117-27.
    Anar C, Bicmen C, Yapicioglu S, et al. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiol. 2010;33(2):117-27.
    Anar, C., Bicmen, C., Yapicioglu, S., Unsal, I., Halilcolar, H., & Yilmaz, U. (2010). Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. The New Microbiologica, 33(2), pp. 117-27.
    Anar C, et al. Evaluation of Clinical Data and Antibody Response Following Influenza Vaccination in Patients With Chronic Obstructive Pulmonary Disease. New Microbiol. 2010;33(2):117-27. PubMed PMID: 20518273.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. AU - Anar,Ceyda, AU - Bicmen,Can, AU - Yapicioglu,Sena, AU - Unsal,Ipek, AU - Halilcolar,Huseyin, AU - Yilmaz,Ufuk, PY - 2010/6/4/entrez PY - 2010/6/4/pubmed PY - 2010/7/21/medline SP - 117 EP - 27 JF - The new microbiologica JO - New Microbiol. VL - 33 IS - 2 N2 - The present study investigated the antibody response against influenza vaccine and also the efficacy of vaccination on clinical findings in patients with Chronic Obstructive Pulmonary Disease (COPD) following influenza vaccination. A total of 82 cases with COPD (44 cases as vaccinated and 38 cases as unvaccinated) were evaluated clinically and 21 healthy volunteers were also included in the study as a control group. Influenza (A and B) Ig M and Ig G parameters were analyzed quantitatively in blood samples of the vaccinated group and healthy volunteers by ELISA method once before vaccination and one month and one year after vaccination. The presence of dyspnoea, increased sputum production and/or purulence were accepted as criteria of acute exacerbation. The number of hospital presentations was significantly lower in the vaccinated group and higher in severe cases with COPD in unvaccinated group. Vaccinated cases in the study group experienced significantly fewer episodes of pneumonia, hospitalization and intensive care. Quantitative influenza (A and B) antibody IgG levels significantly increased in these patients as well. In conclusion, seasonal influenza vaccination with the trivalent influenza split virion vaccine especially in severe or very severe COPD patients who need hospitalization was evaluated as beneficial in clinical use. SN - 1121-7138 UR - https://www.unboundmedicine.com/medline/citation/20518273/Evaluation_of_clinical_data_and_antibody_response_following_influenza_vaccination_in_patients_with_chronic_obstructive_pulmonary_disease_ L2 - http://www.newmicrobiologica.org/PUB/allegati_pdf/2010/2/117.pdf DB - PRIME DP - Unbound Medicine ER -